再鼎医药：2024年艾加莫德指引上调至8000万美元，三款产品在中国获批

研究报告 Research Report 13 Aug 2024 再鼎医药 Zai Lab (9688 HK) 2024 年艾加莫德指引上调至 8000 万美元，三款产品在中国获批 Efgartigimod Guidance Raised to 80mn USD, 3 Products Approved in China [Table_yemei 观点聚焦 1] Investment Focus | --- | --- | |-----------------------------------------------|---------------------| | [Table_Info] 维持优于大市 Maintain OUTPERFORM | | | 评级 | 优于大市 OUTPERFORM | | 现价 | HK$12.50 | | 目标价 | HK$65.76 | | HTI ESG | 2.9-1.5-4.0 | E-S-G: 0-5, (Please refer to the Appendix for ESG comments) | --- | --- | |----------------- ...